Keywords
How to Cite
Abstract
Ph negative myeloproliferative neoplasms (NMP), polycythemia vera (PV), essential thrombocythemia
(ET) and primary myelofibrosis (MF), are clonal hematopoietic disorders characterized in their chronic
phase by an overproduction of differentiated hematopoietic cells. Hydroxyurea (HU) is an antineoplastic
agent belonging to the family of antimetabolites. (According to ELN guidelines, it is recommended as first-line cytoreductive therapy). It is the cytoreductive agent recommended in the first line by the European Leukemia Net (ELN). The aim of this work was to describe the criteria for the initiation of cytoreductive treatment, vascular complications and response rates, intolerance, resistance and progression to myelofibrosis or AML in a population of patients with NMP treated with hydroxyurea in Argentina. 419 patients referred by 63 members of the SAH, belonging to 37 institutions, diagnosed between 1986 and 2017 were included, of which 417 were available for analysis. We observed that the main reason for starting treatment was age (51%), followed by the presence of vascular risk factors (26.6%), thrombocytosis (24.7%) with an average platelet count 1.052 x 109/L (DS 360.32) and previous thrombosis (16.8%). Complete hematological responses lasting at least three months were obtained in PV and TE (61 and 66%). The presence of arterial and venous thrombosis had a similar frequency (14%). The use of HU significantly reduced the risk of thrombosis in the higher risk group. The clinical course and complications of the patients studied with PV JAK2 and positive JAK2 TE were similar and adverse events due to the use of HU were mild but frequent (32.6%).
References
2. Antonilli E, Guglielmelli P, Pieri L y col. Hydroxyurea related toxicity in 3411 patients with Ph negative MPN. Am J Hematol. 2012 Mayo; 87 (5). 552-554.
3. Barbui T, Barosi G, Birgegard G y col. European LeukemiaNet: Philadelphia negative classical myeloproliferative
neoplasms: critical concepts and management recommendations from European Leukemia-Net. J Clin Oncol. 2011; 29: 761-770.
4. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients
with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-6.
5. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia. 2017 update on diagnosis, risk stratification and management. Am J Hematol. 2017;92: 95-108.
6. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC y col. Frequency and prognostic value of resistance/ intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016 Mar;172(5):786-93.
7. Kiladjian J, Chever S, Dosquet C,Chomienne C and Rain JD. Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980. J Clin Oncol. 2011;29:3907-3913.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar